However, when comparing specific targeted approaches (Rindopepimut, or CDX-110, is another -- with an ITT population below 30%) already outlined in two of the studies above, whole tumor lysate-loaded DC vaccines, which express the full array of biomarkers, show stronger effect than highly targeted antigen expressive DC vaccines, such as IMUC's ICT-107. Thus, the results with DCVax-L should exceed those of that study.
Still, there is strong evidence ICT-107 could find its way to approval, should it repeat these results in a large Ph. III trial, but that would take quite a while. By that time, DCVax-L will have long completed its Ph. III trial, and possibly have been granted full approval. Should this occur, IMUC would be required to begin anew, proving effect over the new SOC, namely Temodar + DCVax-L in newly-diagnosed GBM. That would be a much greater task for it to show than simply effectiveness over Temodar (a similar fate may befall AV0113 and CDX-110, basically wasting all of the money and research they had put into proving an advantage over Temodar alone).
It would also lose its ability to take advantage of marketing exclusivity via orphan drug status, having been beat to the punch by NWBO and DCVax-L. NWBO is much further along."
Complete and utter nonsense as it cannot target all the antigens in the same manner, at what stage, at what level of penetration? How in conjunction with checkpoint inhibitors and other factors over T cell regulation?
You are an I D I O T! Period. CLDX is in a much STRONGER position today then when it hit its high of 38.75 a year ago, moron
Are you really that dumb or just pretending to be. They have leashed this "wait time" on quite the long and getting longer leash. What should have been clear, concise clinical information on specifics of who, what where, how of enrollment has NEVER been released. Need to be at minimum 7 months ago, What is it you fail to understand? And ANY. I repeat ANY CEO who ever does battle at each PR one has a matter of BASIC BASIC BASIC common thread of sense should run a fricken mile. But I take it that YOU thing she is protecting shareholder? How kind and gracious of you.
How about starting with the release of specific on enrollment which should have been done MANY MANY moons past. But keep dreaming
That was a fine mighty booth there, with NO ONE home. However, idiots here will pour there money hand over fist
"I am in it to WIN it." So much for your concern cancer patients. You sound like a lottery blurb. May I sell you a bridge dear Sir infantile moron. SLOW and steady into oblivion so shall you go! This will close near 5 or worse. You deserve it, dope
Actually, that is patently false. He rightfully blasts our dear former Enron darling Linda F Powers, concerning the fact amongst other s things she dismissed the fact of the core necessity of checkpoint inhibitors, which ensure that the antigen targeted cell types (oops she
You really now must be kidding? Those above comparison are non-sequiturs. All of the above mentioned have strong legitimate and diverse pipelines, peer reviewed, approved, or advanced trials. Billions in liquidity and institutional investment. Again, you must be kidding. No, no no my want to be sagacious one, not ABOVE 100. Wrong decimal, you do mean above 1.00 which it is NOW officially heading towards
Not such much "a single product with a mechanism of action" rather than immunotherapeutic specified precision targeted cell types. Antigen target groups have to be specified. It cannot just be a blanket approach. Specific class of approval will be based upon effective elimination of the specific antigen cell expression type in addition of course to all the other typical clinical criteria.
The point bballgm is to take responsibility for your misleading statement, dumbell"
"So CLDX has ~3-4 month OS and 2 month PFS benefit. LOL"
Trying for touche, hey boar? No longer pursuing rindo outside of GBM, oh really care to provide the link for that major announcement? BS! They never were presently pursuing in current development other applications, note the phrase in-present. However, they will be targeting other EGFRvIII indications by way of collaboration at the very least., has always been in the cards. Why wouldn't they? Give me a break, you know better now, don't you wise a --- - s. Amazing that you are here you are far too intelligent to be here except as shorting. Perhaps they will halt the same for GPNMB, right? Idiot
Try multibillion dollar potential large diverse pipeline, late phase two, three candidates. Do some basic DD, Go to their website for starters. If you still ask the same question or have question as to I don't get it, etc then you deserve to lose your shirt
That is the purpose of controlled T- Cell regulation, or specific precision targeted immunotherapy that works in conjunction with checkpoint inhibitors and preventing an overimmune T cell responses (TREGs) which is not good. DOes their vaccine work in conjunction with checkpoint inhibitors according to the dear fat lady Linda F the answer is "we do not need to." Really? Hence AF's torpedo article on the wonderful delusional world of Linda F. IN order to go beyond the injection site affect, you need to be able to precision targeted or systemic and penetrate the microcellular environment. SH!
It has always been a goldmine stock If you had money unlike moi to invest, as it is NOT, never has been if or can they, but more adjectives like when and watch out. At the end of the day nothing has changed except the real deal of increased institutional accumulation. 91% Institutions holding and accumulating must tell even the most profound idiot that uh! dud this is "something." lol
This in effect will triple or some multiple exponential Celldex's pipeline worth by billions. This new FDA approval required process coming to a neighborhood to you soon will be one of the best positioning of companies like CLDX